This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
antiviral activity | 344 |
respiratory syndrome | 308 |
virus infection | 251 |
influenza virus | 248 |
infected cells | 216 |
pl pro | 188 |
acute respiratory | 179 |
mg kg | 179 |
syndrome coronavirus | 169 |
herpes simplex | 158 |
virus replication | 157 |
severe acute | 156 |
vero cells | 155 |
simplex virus | 147 |
ebola virus | 131 |
type i | 131 |
middle east | 129 |
east respiratory | 120 |
viral replication | 118 |
viral rna | 112 |
respiratory syncytial | 110 |
respiratory tract | 106 |
syncytial virus | 103 |
cell culture | 103 |
inhibitory effect | 101 |
sukumo extract | 98 |
virus type | 91 |
vaccinia virus | 88 |
cov pl | 87 |
kg day | 87 |
cell lines | 84 |
well plates | 78 |
viral infection | 77 |
sialic acid | 76 |
antiviral drugs | 76 |
influenza viruses | 75 |
amino acid | 73 |
spike protein | 73 |
virus entry | 72 |
inhibitory effects | 72 |
antiviral res | 72 |
lung slices | 71 |
cord uid | 70 |
antiviral agents | 70 |
doc id | 70 |
plaque assay | 70 |
res doi | 70 |
antiviral effect | 69 |
gene expression | 68 |
control group | 66 |
virus titers | 66 |
clinical trials | 65 |
viral dna | 65 |
mg ml | 64 |
rna viruses | 64 |
host cell | 61 |
human immunodeficiency | 61 |
cell surface | 60 |
rna polymerase | 60 |
viral infections | 60 |
immunodeficiency virus | 58 |
viral entry | 58 |
described previously | 58 |
spectrum antiviral | 57 |
inhibitory activity | 57 |
infectious bronchitis | 56 |
infected mice | 56 |
cov infection | 55 |
crystal structure | 54 |
transmissible gastroenteritis | 53 |
western blotting | 53 |
morpholino oligomers | 53 |
virus infections | 53 |
cells infected | 53 |
pfu ml | 53 |
present study | 51 |
nucleocapsid protein | 51 |
pedv pl | 50 |
cell line | 49 |
dromedary camels | 49 |
mouse model | 49 |
sars coronavirus | 49 |
life cycle | 49 |
antiviral research | 48 |
post infection | 48 |
rna interference | 47 |
antiviral therapy | 47 |
three times | 47 |
room temperature | 47 |
cell viability | 47 |
immune response | 46 |
gd protein | 46 |
previously described | 46 |
ebn extract | 46 |
immune responses | 46 |
zika virus | 45 |
i fcov | 45 |
bronchitis virus | 45 |
monoclonal antibody | 45 |
dependent manner | 45 |
negative control | 45 |
cell cultures | 45 |
plaque reduction | 45 |
epithelial cells | 44 |
antiviral drug | 44 |
antiviral effects | 44 |
neutralizing antibodies | 44 |
results showed | 43 |
membrane fusion | 43 |
independent experiments | 43 |
sirna swarms | 42 |
nucleotide analogues | 42 |
dengue virus | 41 |
amc dcba | 41 |
innate immune | 41 |
like protease | 41 |
mouse lung | 41 |
significantly reduced | 41 |
results suggest | 41 |
rna synthesis | 41 |
type ii | 40 |
western blot | 40 |
ex vivo | 40 |
time pcr | 40 |
reverse transcriptase | 40 |
tgev infection | 40 |
lung slice | 40 |
rw peptides | 40 |
nucleic acid | 40 |
amino acids | 39 |
infectious diseases | 39 |
lg ml | 38 |
previous studies | 38 |
viral genome | 38 |
host cells | 38 |
days post | 38 |
parainfluenza virus | 37 |
influenza infection | 37 |
bovine serum | 37 |
chronic hepatitis | 37 |
culture medium | 37 |
treated cells | 37 |
respiratory disease | 36 |
rna replication | 36 |
lower respiratory | 36 |
coronavirus infection | 36 |
novel coronavirus | 36 |
hiv infection | 36 |
dependent rna | 36 |
rna virus | 36 |
public health | 36 |
rsv vaccine | 36 |
infectious peritonitis | 35 |
cells treated | 35 |
results indicate | 35 |
feline infectious | 35 |
specific cd | 34 |
viral diseases | 34 |
structural proteins | 34 |
viral load | 34 |
animal models | 34 |
tissue culture | 34 |
virus yield | 33 |
st cells | 33 |
viral titers | 33 |
hela cells | 33 |
day post | 33 |
enveloped viruses | 33 |
performed using | 33 |
barr virus | 33 |
cleavage site | 33 |
binding site | 33 |
hepatitis virus | 33 |
respiratory viruses | 33 |
vaccine candidates | 33 |
live attenuated | 33 |
fetal bovine | 32 |
clinical signs | 32 |
tgev replication | 32 |
per well | 32 |
increasing concentrations | 32 |
active site | 32 |
dna synthesis | 32 |
luciferase activity | 31 |
may also | 31 |
virus titer | 31 |
entry process | 31 |
important role | 31 |
dna polymerase | 31 |
porcine reproductive | 31 |
binding domain | 31 |
virus exposure | 31 |
antiviral activities | 31 |
liposomal peptides | 31 |
slice model | 30 |
medium containing | 30 |
syndrome virus | 30 |
protein levels | 30 |
viral proteins | 30 |
target cells | 30 |
receptor binding | 30 |
stranded rna | 30 |
dna viruses | 30 |
dub activity | 30 |
reduction assay | 30 |
myricetin may | 30 |
gastroenteritis virus | 29 |
vitro antiviral | 29 |
saudi arabia | 29 |
cell responses | 29 |
monoclonal antibodies | 29 |
fusion protein | 29 |
mice infected | 29 |
cell monolayers | 29 |
viral membrane | 29 |
human coronavirus | 29 |
viral envelope | 29 |
rsv disease | 29 |
highly pathogenic | 29 |
nucleoside analogues | 28 |
highly conserved | 28 |
viral protein | 28 |
ec values | 28 |
antiviral compounds | 28 |
nucleic acids | 28 |
mdck cells | 28 |
protein kinase | 28 |
small molecule | 28 |
immune system | 28 |
respiratory infections | 28 |
cytopathic effect | 28 |
avian influenza | 27 |
binding affinity | 27 |
weight loss | 27 |
rsv infection | 27 |
previously reported | 27 |
final concentration | 27 |
three independent | 27 |
culture supernatants | 27 |
prrsv rna | 27 |
cell entry | 27 |
ic values | 27 |
infectious virus | 26 |
da expected | 26 |
inflammatory response | 26 |
taken together | 26 |
cov rbd | 26 |
mtt assay | 26 |
neutralizing antibody | 26 |
expression levels | 26 |
well tolerated | 26 |
uninfected cells | 26 |
marburg virus | 26 |
cov spike | 26 |
mrna expression | 25 |
upper respiratory | 25 |
viral particles | 25 |
genomic rna | 25 |
hbv dna | 25 |
syncytium formation | 25 |
porcine epidemic | 25 |
dna replication | 25 |
vacv growth | 25 |
time points | 25 |
expressing plasmid | 25 |
sore throat | 25 |
virus challenge | 25 |
plaque formation | 25 |
cellular proteins | 25 |
cholesterol depletion | 25 |
mouth disease | 25 |
reverse genetics | 24 |
neutralizing activity | 24 |
virus activity | 24 |
tract infections | 24 |
binding sites | 24 |
cell membrane | 24 |
total rna | 24 |
cells per | 24 |
disease virus | 24 |
infected patients | 24 |
diarrhea virus | 24 |
i ifn | 24 |
african horse | 24 |
horse sickness | 24 |
data suggest | 24 |
i interferon | 24 |
ctl epitopes | 24 |
potential antiviral | 24 |
phase ii | 24 |
different concentrations | 24 |
various concentrations | 23 |
hcv replication | 23 |
virus glycoprotein | 23 |
hiv activity | 23 |
acid residues | 23 |
serially diluted | 23 |
blot analysis | 23 |
coronavirus spike | 23 |
determined using | 23 |
signaling pathway | 23 |
current study | 23 |
west nile | 23 |
hcv rna | 23 |
data indicate | 23 |
sspe virus | 23 |
cells using | 22 |
like receptor | 22 |
protein synthesis | 22 |
significant difference | 22 |
cell lysates | 22 |
fold increase | 22 |
virus rna | 22 |
hp peptides | 22 |
rd cells | 22 |
mammalian cells | 22 |
viral respiratory | 22 |
potent antiviral | 22 |
drug discovery | 22 |
polymerase reaction | 22 |
buffered saline | 22 |
frhk cells | 22 |
nile virus | 22 |
infected vero | 22 |
specific antiviral | 22 |
time rt | 22 |
da observed | 21 |
determine whether | 21 |
dendritic cells | 21 |
mouse hepatitis | 21 |
effective concentration | 21 |
treated mice | 21 |
therapeutic agents | 21 |
coronavirus nucleocapsid | 21 |
cd tem | 21 |
memory cd | 21 |
epidemic diarrhea | 21 |
phase i | 21 |
immunofluorescence assay | 21 |
cell signaling | 21 |
mouse igg | 21 |
virus strains | 21 |
selectivity index | 21 |
post treatment | 21 |
way anova | 21 |
peritonitis virus | 21 |
influenza vaccine | 21 |
mm tris | 21 |
post virus | 21 |
flow cytometry | 21 |
well plate | 21 |
signaling pathways | 21 |
side chain | 21 |
vaccine candidate | 20 |
positive control | 20 |
rna genome | 20 |
highly effective | 20 |
hrv activity | 20 |
drug development | 20 |
viral infectivity | 20 |
resident memory | 20 |
fever virus | 20 |
hcv infection | 20 |
otitis media | 20 |
binding activity | 20 |
also observed | 20 |
potent anti | 20 |
human cells | 20 |
inhibition assay | 20 |
analyzed using | 20 |
hepg cells | 20 |
crl cells | 20 |
potent inhibitor | 20 |
rrna degradation | 20 |
viral life | 20 |
effective antiviral | 20 |
rna levels | 20 |
sirna swarm | 20 |
rotavirus infection | 20 |
antiviral efficacy | 20 |
filovirus entry | 19 |
nucleoside analogs | 19 |
hemorrhagic fever | 19 |
vacv late | 19 |
hsv infection | 19 |
thymidine kinase | 19 |
ii fcov | 19 |
inhibit viral | 19 |
health organization | 19 |
class i | 19 |
protease inhibitors | 19 |
innate immunity | 19 |
drug resistance | 19 |
small interfering | 19 |
rna degradation | 19 |
clinical use | 19 |
clinical studies | 19 |
natural product | 19 |
prv infection | 19 |
spleen cells | 19 |
sars virus | 19 |
mers coronavirus | 19 |
reduction assays | 19 |
virus particles | 19 |
vaccine development | 19 |
world health | 19 |
graphpad prism | 19 |
high levels | 19 |
gastroenteritis coronavirus | 19 |
antibody titers | 19 |
pmoplus tm | 19 |
recombinant viruses | 19 |
phage display | 18 |
widely used | 18 |
thermo fisher | 18 |
genbank accession | 18 |
virus inoculation | 18 |
supplementary data | 18 |
cl pro | 18 |
vesicular stomatitis | 18 |
ava cells | 18 |
treatment group | 18 |
human respiratory | 18 |
associated coronavirus | 18 |
neu ac | 18 |
virus adsorption | 18 |
mm nacl | 18 |
feline calicivirus | 18 |
tem cells | 18 |
active compounds | 18 |
treatment groups | 18 |
low toxicity | 18 |
broad spectrum | 18 |
mice immunized | 18 |
goat anti | 18 |
peripheral blood | 18 |
quantitative pcr | 18 |
viral attachment | 18 |
virus binding | 18 |
antiviral potency | 18 |
sickness virus | 18 |
cd cd | 18 |
cytotoxic concentration | 18 |
intracellular viral | 18 |
fcov replication | 18 |
significant reduction | 18 |
respiratory viral | 18 |
antiviral action | 18 |
sialic acids | 18 |
similar results | 18 |
vero cell | 18 |
mice treated | 18 |
significantly higher | 18 |
monkey kidney | 18 |
mrna levels | 18 |
cell growth | 18 |
rabbit anti | 17 |
viral shedding | 17 |
specific antibodies | 17 |
coronavirus papain | 17 |
feline coronavirus | 17 |
virus control | 17 |
national institute | 17 |
antimicrobial peptides | 17 |
human parainfluenza | 17 |
throughput screening | 17 |
significantly lower | 17 |
mass spectrometry | 17 |
iu ml | 17 |
two compounds | 17 |
antiviral agent | 17 |
protein expression | 17 |
cell spread | 17 |
two independent | 17 |
culture supernatant | 17 |
statistically significant | 17 |
nervous system | 17 |
nucleoside analog | 17 |
hcv activity | 17 |
new antiviral | 17 |
stomatitis virus | 17 |
monolayer cells | 17 |
health care | 17 |
hong kong | 17 |
viral mrna | 17 |
virucidal activity | 17 |
united states | 17 |
positively charged | 17 |
positron emission | 17 |
serial dilutions | 16 |
gp gene | 16 |
plasma membrane | 16 |
animal model | 16 |
resistant virus | 16 |
protect mice | 16 |
biological activity | 16 |
hcv ns | 16 |
phosphorodiamidate morpholino | 16 |
washed three | 16 |
assay using | 16 |
treated control | 16 |
cell death | 16 |
clinical trial | 16 |
novel antiviral | 16 |
molecular weight | 16 |
kindly provided | 16 |
antisense morpholino | 16 |
secondary antibody | 16 |
also showed | 16 |
recent study | 16 |
specific inhibitors | 16 |
protease activity | 16 |
pcr analysis | 16 |
cultured cells | 16 |
hbv replication | 16 |
closely related | 16 |
hiv replication | 16 |
pet imaging | 16 |
also demonstrated | 16 |
persistently infected | 16 |
wild type | 16 |
least three | 16 |
previous study | 16 |
virus disease | 16 |
body weight | 16 |
zoster virus | 16 |
emission tomography | 16 |
wide range | 16 |
recent studies | 16 |
data presented | 15 |
culture plates | 15 |
prrsv strains | 15 |
immunocompromised patients | 15 |
calculated using | 15 |
cell fusion | 15 |
human influenza | 15 |
leukemia virus | 15 |
spike proteins | 15 |
viral pathogens | 15 |
virology branch | 15 |
growth factor | 15 |
pandemic influenza | 15 |
drug design | 15 |
acid binding | 15 |
raji cells | 15 |
egfr pi | 15 |
ebn extracts | 15 |
sting activation | 15 |
firefly luciferase | 15 |
small molecules | 15 |
strand rna | 15 |
cells transfected | 15 |
block hsv | 15 |
escherichia coli | 15 |
envelope protein | 15 |
inflammatory agents | 15 |
vivo studies | 15 |
virus inoculum | 15 |
fisher scientific | 15 |
nonhuman primates | 15 |
vitro anti | 15 |
cell apoptosis | 15 |
significant differences | 15 |
lead compound | 15 |
host defense | 15 |
also inhibits | 15 |
central nervous | 15 |
novel anti | 15 |
positive cells | 15 |
replication cycle | 15 |
assay system | 15 |
nonstructural protein | 15 |
prrsv replication | 15 |
zikv infection | 15 |
growth medium | 15 |
human coronaviruses | 15 |
avian infectious | 14 |
tyrosine kinase | 14 |
virus strain | 14 |
dcba lozenge | 14 |
mock infected | 14 |
molecule inhibitors | 14 |
conformational change | 14 |
several studies | 14 |
cell types | 14 |
tract disease | 14 |
statistical significance | 14 |
nitric oxide | 14 |
activity relationship | 14 |
treated groups | 14 |
state university | 14 |
real time | 14 |
cellular uptake | 14 |
rna level | 14 |
based assay | 14 |
significantly inhibited | 14 |
fold reduction | 14 |
multiple comparison | 14 |
cellular receptor | 14 |
gel electrophoresis | 14 |
like proteases | 14 |
medium supplemented | 14 |
ml penicillin | 14 |
binding pocket | 14 |
glycyrrhizic acid | 14 |
antibody response | 14 |
cellular receptors | 14 |
structural basis | 14 |
crystal violet | 14 |
survival rate | 14 |
free active | 14 |
reverse transcription | 14 |
antiviral target | 14 |
sense rna | 14 |
optical density | 14 |
naturally occurring | 14 |
i ku | 14 |
virus genome | 14 |
specific primers | 14 |
induced cell | 14 |
virus yields | 14 |
fluorescence intensity | 14 |
respiratory virus | 14 |
early stage | 14 |
lipoic acid | 14 |
human rhinovirus | 14 |
control cells | 14 |
significantly decreased | 14 |
type virus | 14 |
interfering rna | 14 |
high level | 14 |
radionuclide imaging | 14 |
producing cd | 14 |
necrosis factor | 14 |
inhibitory concentration | 14 |
terminal domain | 14 |
causative agent | 13 |
lopinavir ritonavir | 13 |
mycophenolic acid | 13 |
inflammatory drugs | 13 |
pathogenic viruses | 13 |
plaque assays | 13 |
molecular mechanisms | 13 |
activated protein | 13 |
hiv integrase | 13 |
log reduction | 13 |
per group | 13 |
linked liposomal | 13 |
protective immunity | 13 |
approved drugs | 13 |
rna binding | 13 |
yk delta | 13 |
washed twice | 13 |
cytokine mrna | 13 |
cytopathic effects | 13 |
fold higher | 13 |
bacterial sialidases | 13 |
virus vaccine | 13 |
passive transfer | 13 |
microtiter plates | 13 |
also used | 13 |
solution containing | 13 |
duck enteritis | 13 |
therapeutic strategies | 13 |
heptad repeat | 13 |
virus growth | 13 |
following virus | 13 |
per day | 13 |
tumor necrosis | 13 |
capsid protein | 13 |
bd biosciences | 13 |
north american | 13 |
side effects | 13 |
virus gd | 13 |
virus production | 13 |
resistant strains | 13 |
peptidyl substrate | 13 |
human hepatoma | 13 |
reaction buffer | 13 |
conjugated goat | 13 |
host immune | 13 |
essential medium | 13 |
protects mice | 13 |
ng ml | 13 |
cells via | 13 |
mediated antiviral | 13 |
lethal dose | 13 |
coronaviral pl | 13 |
medical research | 13 |
yeast strains | 13 |
lethal influenza | 13 |
envelope glycoprotein | 13 |
dependent enhancement | 13 |
enveloped virus | 13 |
exonuclease activity | 13 |
derived peptides | 13 |
binding protein | 13 |
per cell | 13 |
coronavirus infections | 13 |
oral administration | 13 |
murine leukemia | 13 |
inflammatory effects | 13 |
urgently needed | 13 |
host factors | 13 |
therapeutic effect | 13 |
standard deviation | 13 |
inhibit replication | 13 |
plate reader | 13 |
pedv infection | 13 |
vivo experiments | 12 |
african green | 12 |
also significantly | 12 |
polymerase chain | 12 |
potential anti | 12 |
entry inhibitors | 12 |
well microtiter | 12 |
multiple steps | 12 |
luciferase expressed | 12 |
antiviral compound | 12 |
pre post | 12 |
vp vaccination | 12 |
neu gc | 12 |
pbs containing | 12 |
ifn treatment | 12 |
comparison tests | 12 |
virus lung | 12 |
oh group | 12 |
virus inhibition | 12 |
chain reaction | 12 |
ppmo treatment | 12 |
matrix protein | 12 |
ck ch | 12 |
may serve | 12 |
human cytomegalovirus | 12 |
virus infectivity | 12 |
even though | 12 |
sequence alignment | 12 |
empty vector | 12 |
point mutations | 12 |
might also | 12 |
virus ns | 12 |
protein vp | 12 |
fusion peptide | 12 |
evaluated using | 12 |
vero slam | 12 |
hhd mice | 12 |
recent years | 12 |
oral bioavailability | 12 |
results demonstrate | 12 |
inhibited replication | 12 |
time quantitative | 12 |
immunosorbent assay | 12 |
converting enzyme | 12 |
coronavirus rna | 12 |
treated animals | 12 |
virulent ibv | 12 |
infected individuals | 12 |
incubation period | 12 |
reduced viral | 12 |
cell type | 12 |
morpholino oligomer | 12 |
protective effect | 12 |
reported previously | 12 |
protease inhibitor | 12 |
respiratory pathogens | 12 |
research center | 12 |
virus infected | 12 |
analysis revealed | 12 |
inhibit sars | 12 |
based therapeutics | 12 |
virus expressing | 12 |
using graphpad | 12 |
phosphate buffer | 12 |
expression plasmids | 12 |
virus vaccines | 12 |
two different | 12 |
inhibit virus | 12 |
conjugated morpholino | 12 |
antisense oligomers | 12 |
ml streptomycin | 12 |
measured using | 12 |
inhibitory activities | 12 |
high affinity | 12 |
oligoadenylate synthetase | 12 |
also tested | 12 |
may interact | 12 |
fluorescent protein | 12 |
authors declare | 12 |
terminal region | 12 |
viral titer | 12 |
enzymatic activity | 12 |
viral gene | 12 |
rsv groups | 12 |
fold lower | 12 |
open reading | 11 |
xc plaque | 11 |
kinetic parameters | 11 |
reduced virus | 11 |
gvn center | 11 |
micromolar range | 11 |
slam cells | 11 |
indicated concentrations | 11 |
imaging probes | 11 |
rift valley | 11 |
specific ctls | 11 |
human airway | 11 |
luciferase assay | 11 |
glycopeptide antibiotics | 11 |
nucleoside phosphonates | 11 |
investigated whether | 11 |
chain termination | 11 |
pfu per | 11 |
approved antiviral | 11 |
error bars | 11 |
piv activity | 11 |
target site | 11 |
respiratory illness | 11 |
data obtained | 11 |
antiviral response | 11 |
morpholino antisense | 11 |
potent inhibitory | 11 |
applied biosystems | 11 |
tcid ml | 11 |
chemokine receptor | 11 |
orally bioavailable | 11 |
secondary structure | 11 |
mice receiving | 11 |
treated viruses | 11 |
using anti | 11 |
containing mm | 11 |
akt pathway | 11 |
modified vaccinia | 11 |
peptide rbd | 11 |
green monkey | 11 |
blood cells | 11 |
coronavirus replication | 11 |
linear regression | 11 |
recipient mice | 11 |
viral disease | 11 |
late gene | 11 |
wt vacv | 11 |
liposomal peptide | 11 |
antibody responses | 11 |
fcov infection | 11 |
active substances | 11 |
chikungunya virus | 11 |
different time | 11 |
much less | 11 |
emerging viruses | 11 |
delayed termination | 11 |
peptide library | 11 |
inflammatory activities | 11 |
broad range | 11 |
therapeutic index | 11 |
based assays | 11 |
placebo lozenge | 11 |
linked immunosorbent | 11 |
product extracts | 11 |
human ifitm | 11 |
attenuated influenza | 11 |
highly significant | 11 |
previously shown | 11 |
valley fever | 11 |
adapted sars | 11 |
van der | 11 |
fipv cl | 11 |
cell proliferation | 11 |
emerging viral | 11 |
heme oxygenase | 11 |
cotton rats | 11 |
lethal sars | 11 |
diseases caused | 11 |
confocal microscopy | 11 |
viral antigen | 11 |
virus stock | 11 |
cell epitopes | 11 |
interfering rnas | 11 |
treated group | 11 |
antiviral properties | 11 |
squaric acid | 11 |
young children | 11 |
measles virus | 11 |
immunized mice | 11 |
dna polymerases | 11 |
results indicated | 11 |
cell infection | 11 |
vaccinated chickens | 11 |
crystal structures | 11 |
ch ldl | 11 |
prrsv yield | 11 |
currently available | 11 |
inactivated vaccine | 11 |
stranded dna | 11 |
van den | 11 |
peptides derived | 11 |
gene products | 11 |
like cleavage | 11 |
receptor tyrosine | 11 |
based system | 11 |
parainfluenza viruses | 11 |
transgenic mice | 11 |
respiratory coronavirus | 10 |
murine hepatitis | 10 |
significant inhibition | 10 |
results suggested | 10 |
drug resistant | 10 |
rega institute | 10 |
mm hepes | 10 |
animal experiments | 10 |
enteritis virus | 10 |
free virus | 10 |
results show | 10 |
adverse effects | 10 |
human papillomavirus | 10 |
gd gene | 10 |
five days | 10 |
viral strains | 10 |
main protease | 10 |
inhibited virus | 10 |
structural protein | 10 |
quantitative rt | 10 |
vacv dna | 10 |
mediated immunity | 10 |
biosafety level | 10 |
significant inhibitory | 10 |
antigen expression | 10 |
lung titers | 10 |
target cell | 10 |
lung tissue | 10 |
gene silencing | 10 |
dependent inhibition | 10 |
monocytes macrophages | 10 |
viral polymerase | 10 |
also investigated | 10 |
vaccinated mice | 10 |
il tm | 10 |
spinal cord | 10 |
pfu cell | 10 |
specific imaging | 10 |
specific monoclonal | 10 |
effectively inhibit | 10 |
envelope glycoproteins | 10 |
accession number | 10 |
fatality rates | 10 |
polygonum tinctorium | 10 |
catalytic core | 10 |
translation initiation | 10 |
nucleocapsid proteins | 10 |
primary human | 10 |
rsv vaccines | 10 |
target viral | 10 |
lysis buffer | 10 |
relevant peptide | 10 |
entry site | 10 |
drug combination | 10 |
twice daily | 10 |
binding assay | 10 |
clinical symptoms | 10 |
virus attachment | 10 |
epitopes derived | 10 |
surface glycoproteins | 10 |
disease control | 10 |
one week | 10 |
least two | 10 |
spike glycoprotein | 10 |
human lung | 10 |
ebv infection | 10 |
mm atp | 10 |
indicated time | 10 |
dmem supplemented | 10 |
highly specific | 10 |
reporter gene | 10 |
virus neutralization | 10 |
national institutes | 10 |
sequence analysis | 10 |
following incubation | 10 |
tm kopf | 10 |
nc sirna | 10 |
feline monocytes | 10 |
intrinsic disorder | 10 |
rich peptide | 10 |
bronchoalveolar lavage | 10 |
guinea pigs | 10 |
inhibited hcv | 10 |
fresh medium | 10 |
attenuated vaccine | 10 |
chronic infection | 10 |
secreting cd | 10 |
cells expressing | 10 |
acyclic nucleoside | 10 |
imaging probe | 10 |
cholesterol transporter | 10 |
den born | 10 |
pharmacokinetic properties | 10 |
acute otitis | 10 |
effective concentrations | 10 |
completely inhibited | 10 |
sting agonist | 10 |
cov replication | 10 |
inhibited hiv | 10 |
suckling mice | 10 |
low cytotoxicity | 10 |
placebo group | 10 |
ethacrynic acid | 10 |
mononuclear cells | 10 |
antiviral assays | 10 |
infectious disease | 10 |
ec value | 10 |
cells grown | 10 |
also shown | 10 |
test compounds | 10 |
red blood | 10 |
low ph | 10 |
reaction mixture | 10 |
calf serum | 10 |
viral transcripts | 10 |
technical meeting | 10 |
dev clone | 10 |
vitro activity | 10 |
experiments performed | 10 |
quadruplex forming | 10 |
biochemical assays | 10 |
may inhibit | 10 |
results demonstrated | 10 |
high throughput | 10 |
dromedary camel | 10 |
unmodified ul | 10 |
functional analysis | 10 |
much higher | 10 |
antiviral treatment | 10 |
new class | 10 |
biological activities | 10 |
vivo efficacy | 10 |
novel therapeutic | 10 |
cholesterol accumulation | 10 |
pseudorabies virus | 9 |
research institute | 9 |
streptococcus pneumoniae | 9 |
early stages | 9 |
investigate whether | 9 |
lg well | 9 |
lymphocytic choriomeningitis | 9 |
intracellular trafficking | 9 |
caspase activation | 9 |
hiv transmission | 9 |
therapeutic effects | 9 |
assays using | 9 |
animal studies | 9 |
liquid chromatography | 9 |
patients infected | 9 |
ace receptor | 9 |
forming units | 9 |
human transmission | 9 |
cp strains | 9 |
foster city | 9 |
coding sequence | 9 |
cancer patients | 9 |
less effective | 9 |
lassa virus | 9 |
drug screening | 9 |
cells pretreated | 9 |
administered orally | 9 |
mm utp | 9 |
respiratory diseases | 9 |
primer pair | 9 |
gd proteins | 9 |
family coronaviridae | 9 |
control mice | 9 |
viral spread | 9 |
induced cpe | 9 |
urgent need | 9 |
endoplasmic reticulum | 9 |
rna polymerases | 9 |
receptor ace | 9 |
drug delivery | 9 |
pam cells | 9 |
kidney cells | 9 |
hiv rna | 9 |
ifn response | 9 |
plasma samples | 9 |
represent mean | 9 |
chemically synthesized | 9 |
high mortality | 9 |
pfu mouse | 9 |
virus life | 9 |
treated controls | 9 |
active triphosphate | 9 |
jnk phosphorylation | 9 |
viral fusion | 9 |
yellow fever | 9 |
epithelial cell | 9 |
elisa assay | 9 |
first time | 9 |
mortality rates | 9 |
virucidal activities | 9 |
virucidal effect | 9 |
herpes virus | 9 |
intravenous administration | 9 |
iga antibodies | 9 |
clinically approved | 9 |
indirect immunofluorescence | 9 |
humanized monoclonal | 9 |
vp protein | 9 |
viral genomic | 9 |
fipv inoculation | 9 |
intracellular cholesterol | 9 |
tcid values | 9 |
infections caused | 9 |
plaque forming | 9 |
persistent infection | 9 |
hepatocellular carcinoma | 9 |
rsv epitopes | 9 |
cytotoxic effects | 9 |
sting agonists | 9 |
acid sequence | 9 |
control groups | 9 |
expression level | 9 |
viability assay | 9 |
rna molecule | 9 |
lethal infection | 9 |
endothelial cells | 9 |
hepatoma cell | 9 |
cpe development | 9 |
showed significant | 9 |
pcr assay | 9 |
lipid rafts | 9 |
surface protein | 9 |
interferon alpha | 9 |
antiviral mechanism | 9 |
viral glycoprotein | 9 |
molecular biology | 9 |
transfected cells | 9 |
treatment options | 9 |
influenza activity | 9 |
hbv infection | 9 |
luciferase reporter | 9 |
ms ms | 9 |
utah state | 9 |
host interactions | 9 |
antiviral responses | 9 |
binding mode | 9 |
functional receptor | 9 |
hydrogen bond | 9 |
cover layer | 9 |
vp vaccinated | 9 |
pathogenic human | 9 |
systematic review | 9 |
mrna cap | 9 |
gfp signal | 9 |
rna molecules | 9 |
conserved among | 9 |
hexylresorcinol lozenge | 9 |
expression vector | 9 |
infection inhibition | 9 |
conjugated anti | 9 |
nucleoside analogue | 9 |
activity assay | 9 |
untreated control | 9 |
scorpion venom | 9 |
drug administration | 9 |
catalytic activity | 9 |
agarose gel | 9 |
hepatoma cells | 9 |
hla class | 9 |
ic value | 9 |
lm thick | 9 |
administered i | 9 |
yeast cells | 9 |
antiviral therapies | 9 |
green fluorescent | 9 |
family members | 9 |
host innate | 9 |
interferon therapy | 9 |
antiviral strategies | 9 |
human disease | 9 |
human receptor | 9 |
fusion domain | 9 |
mtase activity | 9 |
induced inflammation | 9 |
seneca valley | 9 |
minimum essential | 9 |
combination therapy | 9 |
ii ccov | 9 |
direct interaction | 9 |
contact time | 9 |
compounds will | 9 |
analysis showed | 9 |
drug concentrations | 9 |
horseradish peroxidase | 9 |
lavage fluid | 9 |
data indicated | 9 |
also inhibited | 9 |
murine coronavirus | 9 |
mm phosphate | 9 |
factor alpha | 9 |
valley virus | 9 |
brain barrier | 9 |
human infection | 9 |
std nmr | 9 |
th icar | 9 |
entry steps | 9 |
entry step | 9 |
subgenomic rna | 9 |
vivo model | 9 |
rsv replication | 9 |
vaccine strain | 9 |
antiviral mechanisms | 9 |
lung weights | 9 |
choriomeningitis virus | 9 |
side chains | 9 |
tcid assay | 9 |
global technical | 9 |
treated virus | 9 |
charged pmos | 9 |
within days | 9 |
rabbit igg | 9 |
virus dna | 9 |
chronically infected | 8 |
adoptive transfer | 8 |
microbial natural | 8 |
newcastle disease | 8 |
high dose | 8 |
phase iii | 8 |
inhibits hepatitis | 8 |
time point | 8 |
specific sirna | 8 |
log pfu | 8 |
nuclear factor | 8 |
ns protein | 8 |
transmembrane protein | 8 |
live dead | 8 |
disulfiram may | 8 |
cholesterol biosynthesis | 8 |
fold dilutions | 8 |
new strain | 8 |
cellular cholesterol | 8 |
severe respiratory | 8 |
adverse events | 8 |
unmodified sirna | 8 |
findings suggest | 8 |
virus nonstructural | 8 |
hsv binding | 8 |
ebv replication | 8 |
virus transmission | 8 |
may lead | 8 |
mean day | 8 |
novel mechanism | 8 |
core protein | 8 |
hydroxyl group | 8 |
aglycoristocetin derivatives | 8 |
may help | 8 |
recently reported | 8 |
human herpesvirus | 8 |
culture infectious | 8 |
cowpox virus | 8 |
surface glycoprotein | 8 |
rabies virus | 8 |
therapeutic options | 8 |
bovine viral | 8 |
intranasal infection | 8 |
potential drug | 8 |
dna sequencing | 8 |
hsv gd | 8 |
structural features | 8 |
neutrally charged | 8 |
flow cytometric | 8 |
scale bar | 8 |
many viruses | 8 |
past years | 8 |
expression plasmid | 8 |
infectious dose | 8 |
separate experiments | 8 |
assay kit | 8 |
ca atoms | 8 |
surface gp | 8 |
cell epitope | 8 |
tract infection | 8 |
also evaluated | 8 |
lm group | 8 |
inflammatory cytokines | 8 |
blood products | 8 |
adsorption step | 8 |
single stranded | 8 |
mm edta | 8 |
high risk | 8 |
inflammatory activity | 8 |
kinase inhibitors | 8 |
primary antibodies | 8 |
entry inhibitor | 8 |
takes place | 8 |
overnight incubation | 8 |
relatively low | 8 |
selective inhibitor | 8 |
dose dependent | 8 |
completely abolished | 8 |
protein structure | 8 |
science foundation | 8 |
polyclonal antibody | 8 |
viral targets | 8 |
study group | 8 |
hiv rt | 8 |
two viruses | 8 |
north carolina | 8 |
data represent | 8 |
rpe cells | 8 |
atcc vr | 8 |
mice per | 8 |
cov nsp | 8 |
drug levels | 8 |
new coronavirus | 8 |
sars cov | 8 |
infected pk | 8 |
molecular tweezer | 8 |
health concern | 8 |
three separate | 8 |
scnj tlr | 8 |
molecular docking | 8 |
pedv particles | 8 |
late proteins | 8 |
immunodetection assay | 8 |
regulatory factor | 8 |
point mutation | 8 |
zoonotic transmission | 8 |
ns protease | 8 |
cc values | 8 |
dmso treatment | 8 |
bacterial infection | 8 |
viral genomes | 8 |
encephalitis virus | 8 |
serum antibody | 8 |
santa cruz | 8 |
interferon induction | 8 |
antibody levels | 8 |
every days | 8 |
virus receptor | 8 |
viral activity | 8 |
inflammatory responses | 8 |
rsv challenge | 8 |
viral diarrhea | 8 |
dosing regimens | 8 |
ml griffithsin | 8 |
cellular factors | 8 |
sexual transmission | 8 |
vaccinated groups | 8 |
lung disease | 8 |
studies showed | 8 |
passive immunisation | 8 |
target sequence | 8 |
coronavirus associated | 8 |
important roles | 8 |
resistant mutants | 8 |
determined relative | 8 |
polymerase inhibitors | 8 |
large number | 8 |
ascorbic acid | 8 |
survival time | 8 |
early step | 8 |
cell number | 8 |
strain ck | 8 |
inflammatory cytokine | 8 |
high concentration | 8 |
target sequences | 8 |
viruses expressing | 8 |
attractive target | 8 |
attenuating mutations | 8 |
control virus | 8 |
protein production | 8 |
mutant virus | 8 |
specific binding | 8 |
pg ml | 8 |
cell system | 8 |
bacterial sialidase | 8 |
two mutations | 8 |
neutralizing mabs | 8 |
viral titre | 8 |
female balb | 8 |
pyrimidine biosynthesis | 8 |
green fluorescence | 8 |
naturally processed | 8 |
latent hiv | 8 |
wt dev | 8 |
quadruplex structures | 8 |
mediated activation | 8 |
viral resistance | 8 |
also known | 8 |
rna cap | 8 |
hsv entry | 8 |
cells ml | 8 |
cellular immune | 8 |
studies suggest | 8 |
oxidative stress | 8 |
inhibits viral | 8 |
without myricetin | 8 |
maintenance medium | 8 |
studies will | 8 |
drug concentration | 8 |
heparan sulfate | 8 |
negatively charged | 8 |
interferon signaling | 8 |
contact times | 8 |
neutralization assay | 8 |
ifn alfacon | 8 |
na activity | 8 |
gl derivatives | 8 |
double stranded | 8 |
per mouse | 8 |
clinical isolates | 8 |
virus surface | 8 |
lithium chloride | 8 |
like receptors | 8 |
equal volume | 8 |
varicella zoster | 8 |
vitro biochemical | 8 |
wide variety | 8 |
mrna capping | 8 |
serum samples | 8 |
aromatic residues | 8 |
significantly different | 8 |
thank dr | 8 |
synthetic peptides | 8 |
interferon system | 8 |
poxvirus infections | 8 |
units ml | 8 |
considered statistically | 8 |
elimination half | 8 |
significantly increased | 8 |
following influenza | 8 |
vivo models | 8 |
statistical analysis | 8 |
drug candidates | 8 |
using cell | 8 |
limited number | 8 |
target rna | 8 |
host cellular | 7 |
potential therapeutic | 7 |
rsv infections | 7 |
hydrophobic side | 7 |
human population | 7 |
rpmi medium | 7 |
dodecyl sulfate | 7 |
dna laddering | 7 |
reporter plasmid | 7 |
virus hemagglutinin | 7 |
lung virus | 7 |
water molecules | 7 |
wr virus | 7 |
age groups | 7 |
gene deletion | 7 |
proteolytic activity | 7 |
pdb id | 7 |
indicated times | 7 |
pr virus | 7 |
ul gene | 7 |
standard deviations | 7 |
first line | 7 |
model may | 7 |
cov vlps | 7 |
new york | 7 |
cd domain | 7 |
animal species | 7 |
earlier studies | 7 |
neutralising antibodies | 7 |
graduate school | 7 |
antiviral studies | 7 |
tm agents | 7 |
biological replicates | 7 |
oxygen atom | 7 |
vaccine design | 7 |
significant increase | 7 |
new anti | 7 |
different clr | 7 |
i interferons | 7 |
rapid diagnosis | 7 |
blood mononuclear | 7 |
nucleotide analog | 7 |
isar news | 7 |
intranasal administration | 7 |
resistant viral | 7 |
different viruses | 7 |
nucleotide analogue | 7 |
porcine respiratory | 7 |
pd peptides | 7 |
may play | 7 |
specific inhibitor | 7 |
prrsv genomic | 7 |
prrsv genome | 7 |
critical role | 7 |
na rsv | 7 |
inhibit influenza | 7 |
binding step | 7 |
inhibitory concentrations | 7 |
like particles | 7 |
mouse models | 7 |
genome replication | 7 |
subacute sclerosing | 7 |
yield inhibition | 7 |
clinical outcome | 7 |
much lower | 7 |
maximum non | 7 |
corona virus | 7 |
american prrsv | 7 |
recognizes residues | 7 |
future studies | 7 |
yield reduction | 7 |
mg cells | 7 |
nmr spectroscopy | 7 |
coronavirus disease | 7 |
highly selective | 7 |
based vaccine | 7 |
rsv titers | 7 |
human health | 7 |
cell cycle | 7 |
camel vaccine | 7 |
many different | 7 |
infection identification | 7 |
full protection | 7 |
mem containing | 7 |
million people | 7 |
rights reserved | 7 |
analysis indicated | 7 |
effective therapeutic | 7 |
initial velocity | 7 |
hbv activity | 7 |
laboratory animals | 7 |
live virus | 7 |
spectrum antivirals | 7 |
total volume | 7 |
different doses | 7 |
play important | 7 |
cov infections | 7 |
induced membrane | 7 |
egfp cells | 7 |
active ingredients | 7 |
dextran sulfate | 7 |
inhibit mers | 7 |
elisa plates | 7 |
dna vaccine | 7 |
viral challenge | 7 |
containing fbs | 7 |
synthetic peptide | 7 |
toxic concentration | 7 |
antiviral immunity | 7 |
san diego | 7 |
laiv na | 7 |
three different | 7 |
three yeast | 7 |
taq polymerase | 7 |
clr concentrations | 7 |
seronegative infants | 7 |
egfp expression | 7 |
defense mechanisms | 7 |
chemical structure | 7 |
acting antiviral | 7 |
virus agent | 7 |
rsv group | 7 |
viral particle | 7 |
coronavirus nsp | 7 |
calicivirus infection | 7 |
global health | 7 |
mg per | 7 |
interferon inducer | 7 |
data showed | 7 |
neutralization assays | 7 |
virus clearance | 7 |
antisense oligonucleotides | 7 |
inflammatory cells | 7 |
human plasma | 7 |
protein interaction | 7 |
risk factors | 7 |
growth cycle | 7 |
denv mtase | 7 |
blotting assay | 7 |
enzymatic activities | 7 |
new world | 7 |
viral antigens | 7 |
vaccine viruses | 7 |
may contribute | 7 |
human cases | 7 |
virion surface | 7 |
versus pss | 7 |
antigenic variation | 7 |
chemical properties | 7 |
host range | 7 |
influenza hemagglutinin | 7 |
proteasome system | 7 |
may provide | 7 |
fluorescence microscopy | 7 |
viral nucleic | 7 |
fatality rate | 7 |
novel inhibitors | 7 |
clinical manifestations | 7 |
triphosphate forms | 7 |
severe disease | 7 |
three mice | 7 |
receptor antagonist | 7 |
lethal challenge | 7 |
significant effect | 7 |
culture plate | 7 |
alveolar macrophages | 7 |
task force | 7 |
viral vector | 7 |
virus variants | 7 |
neutralizing ability | 7 |
zikv immunodetection | 7 |
data associated | 7 |
protein may | 7 |
svv infection | 7 |
block viral | 7 |
stem cells | 7 |
common cold | 7 |
particular interest | 7 |
inhibition assays | 7 |
pcr using | 7 |
residue cys | 7 |
rna complex | 7 |
stock solutions | 7 |
bulgarian academy | 7 |
reduce viral | 7 |
cell control | 7 |
scientific research | 7 |
domain complexed | 7 |
bone marrow | 7 |
examined whether | 7 |
ns rsv | 7 |
protein binds | 7 |
medium alone | 7 |
potent inhibitors | 7 |
inhibit vacv | 7 |
tdf ftc | 7 |
inhibit hsv | 7 |
pairwise comparisons | 7 |
based zikv | 7 |
mediated immune | 7 |
percent inhibition | 7 |
human hepatitis | 7 |
kidney epithelial | 7 |
online version | 7 |
rna isolation | 7 |
prodrug strategy | 7 |
ppmos directed | 7 |
dosing regimen | 7 |
care facilities | 7 |
transcription factors | 7 |
human serum | 7 |
serial passage | 7 |
significant antiviral | 7 |
peptides rbd | 7 |
rna template | 7 |
healthy volunteers | 7 |
major role | 7 |
virtual screening | 7 |
sifitm cells | 7 |
target effects | 7 |
intracellular expression | 7 |
genome sequence | 7 |
ifn production | 7 |
virus induced | 7 |
ppmo targeting | 7 |
cause severe | 7 |
ifn signaling | 7 |
response curves | 7 |
better understanding | 7 |
infected balb | 7 |
fipv strain | 7 |
modular organization | 7 |
different times | 7 |
molecular tweezers | 7 |
glycopeptide compounds | 7 |
acetylneuraminic acid | 7 |
administered intranasally | 7 |
body temperature | 7 |
ann arbor | 7 |
target sites | 7 |
viruses used | 7 |
myricetin treatment | 7 |
celastrol treatment | 7 |
dramatically reduced | 7 |
national health | 7 |
sodium dodecyl | 7 |
western hemisphere | 7 |
polymerase inhibitor | 7 |
antisense molecules | 7 |
recently shown | 7 |
vaccine virus | 7 |
proprotein convertases | 7 |
two days | 7 |
clinical development | 7 |
antisense ppmo | 7 |
pancreatic enzyme | 7 |
ibv strain | 7 |
lipid raft | 7 |
poly ic | 7 |
may act | 7 |
mean values | 7 |
reading frame | 7 |
epitope mapping | 7 |
nonstructural proteins | 7 |
acid amide | 7 |
prevent hiv | 7 |
virus protein | 7 |
wt virus | 7 |
statistical analyses | 7 |
gilead sciences | 7 |
also show | 7 |
confer resistance | 7 |
mitochondrial dna | 7 |
either synthetic | 7 |
mtase inhibitors | 7 |
well cell | 7 |
clone cells | 7 |
highly potent | 7 |
depleted mtase | 7 |
conformational changes | 7 |
two pl | 7 |
laiv ns | 7 |
potently inhibit | 7 |
previously demonstrated | 7 |
addition assay | 7 |
containing co | 7 |
activity relationships | 7 |
veroe tmprss | 7 |
culture media | 7 |
mouse anti | 7 |
post transfection | 7 |
viral loads | 7 |
antiviral molecules | 7 |
whether celastrol | 7 |
years old | 7 |
surface receptor | 7 |
cellular entry | 7 |
clinical score | 7 |
avian flu | 7 |
vivo activity | 7 |
two groups | 7 |
sclerosing panencephalitis | 7 |
modified sirna | 7 |
containing fetal | 7 |
factor receptor | 7 |
epidermal growth | 7 |
microplate reader | 7 |
rate constant | 6 |
knockdown cells | 6 |
inactivated fetal | 6 |
trypan blue | 6 |
polyacrylamide gel | 6 |
result indicates | 6 |
protected mice | 6 |
primary antibody | 6 |
internal ribosome | 6 |
early steps | 6 |
values represent | 6 |
among different | 6 |
medical branch | 6 |
one assay | 6 |
infected cell | 6 |
approved drug | 6 |
value significance | 6 |
sugar chains | 6 |
hantaan virus | 6 |
wuhan institute | 6 |
signal intensity | 6 |
interferon regulatory | 6 |
well culture | 6 |
flavivirus ns | 6 |
npc function | 6 |
pfu well | 6 |
survival rates | 6 |
fusion proteins | 6 |
start site | 6 |
immunocompromised adults | 6 |
eluted fractions | 6 |
biological processes | 6 |
dead cells | 6 |
immune cells | 6 |
prodrug forms | 6 |
gene gapdh | 6 |
rna translation | 6 |
acute infection | 6 |
binding stage | 6 |
virus types | 6 |
way analysis | 6 |
protein interacts | 6 |
cleavage sites | 6 |
two distinct | 6 |
cytotoxic effect | 6 |
acting antivirals | 6 |
statistically analyzed | 6 |
case fatality | 6 |
pedv activity | 6 |
fd ap | 6 |
remains unclear | 6 |
potent inhibition | 6 |
papainlike protease | 6 |
fluorescence microscope | 6 |
specific activity | 6 |
per ml | 6 |
enzyme activity | 6 |
kinase inhibitor | 6 |
target protein | 6 |
resistance development | 6 |
neutral red | 6 |
protective efficacy | 6 |
genital herpes | 6 |
evaluate whether | 6 |
marburg viruses | 6 |
hsv infected | 6 |
better protection | 6 |
spectrum anti | 6 |
coronavirus infectious | 6 |
first report | 6 |
treated tgev | 6 |
flanking amino | 6 |
known antiviral | 6 |
cysteine proteases | 6 |
gene therapy | 6 |
antiretroviral therapy | 6 |
enzymatic cleavage | 6 |
markedly improved | 6 |
animal care | 6 |
older children | 6 |
spectrum inhibitor | 6 |
selective inhibitors | 6 |
agar overlay | 6 |
ppmo target | 6 |
previous findings | 6 |
performance liquid | 6 |
adenovirus type | 6 |
inhibits infection | 6 |
intracellular ifn | 6 |
plasma elimination | 6 |
cell morphology | 6 |
high degree | 6 |
prrsv infection | 6 |
human embryonic | 6 |
highly immunogenic | 6 |
total number | 6 |
cell activation | 6 |
days later | 6 |
quadruplex ligand | 6 |
normal control | 6 |
experimental data | 6 |
young infants | 6 |
drugs targeting | 6 |
labeled probe | 6 |
risk infants | 6 |
lipoic acids | 6 |
ug ml | 6 |
plaque number | 6 |
log tcid | 6 |
coding region | 6 |
vitro experiments | 6 |
concentration required | 6 |
using lipofectamine | 6 |
compounds containing | 6 |
developing new | 6 |
seasonal influenza | 6 |
cell density | 6 |
dengue vaccine | 6 |
two weeks | 6 |
cov entry | 6 |
viral exonuclease | 6 |
induced cytopathic | 6 |
virus titration | 6 |
therapeutic drug | 6 |
apoptosis induced | 6 |
clinical management | 6 |
severe covid | 6 |
sexual intercourse | 6 |
rat model | 6 |
substrate specificity | 6 |
replication may | 6 |
oral doses | 6 |
cells well | 6 |
almost completely | 6 |
tar rna | 6 |
best fit | 6 |
late endosomes | 6 |
rational design | 6 |
strong antiviral | 6 |
fold serial | 6 |
various long | 6 |
tissue tropism | 6 |
immune activation | 6 |
viral capsid | 6 |
human viruses | 6 |
antisense agents | 6 |
mm stock | 6 |
cells compared | 6 |
sting pathway | 6 |
markedly reduced | 6 |
group compared | 6 |
respiratory epithelium | 6 |
adsorption period | 6 |
viral proteases | 6 |
right panel | 6 |
middle ear | 6 |
ribosome entry | 6 |
generated using | 6 |
sialidase fusion | 6 |
nucleotide mismatches | 6 |
sephadex tm | 6 |
synergistic effect | 6 |
lassa fever | 6 |
whether clr | 6 |
dimerization domain | 6 |
several viruses | 6 |
maternal antibodies | 6 |
gastrointestinal tract | 6 |
culture system | 6 |
plasmid pcdna | 6 |
mm dtt | 6 |
concentration range | 6 |
fetal calf | 6 |
influenza pandemic | 6 |
extracellular virus | 6 |
phosphate buffered | 6 |
clinically used | 6 |
viral plaque | 6 |
rna decay | 6 |
cd receptor | 6 |
housekeeping gene | 6 |
dead staining | 6 |
ten years | 6 |
three peptides | 6 |
viral inoculum | 6 |
capping apparatus | 6 |
media containing | 6 |
viable cells | 6 |
minigenome rescue | 6 |
blood samples | 6 |
conserved residues | 6 |
also reported | 6 |
highly sensitive | 6 |
chamber slides | 6 |
macaque model | 6 |
hbv cccdna | 6 |
exogenous ifn | 6 |
viral glycoproteins | 6 |
international conference | 6 |
proteins expressed | 6 |
noncompetitive inhibition | 6 |
exhibited potent | 6 |
drug treatment | 6 |
sialidase activity | 6 |
single point | 6 |
confocal microscope | 6 |
little effect | 6 |
sirnas targeted | 6 |
neither ea | 6 |
group received | 6 |
novel activities | 6 |
i ucd | 6 |
chemokine responses | 6 |
calix arene | 6 |
phi rdrp | 6 |
calculated according | 6 |
neuraminidase inhibitor | 6 |
genetic barrier | 6 |
new drug | 6 |
viruses belonging | 6 |
following convention | 6 |
oral ntz | 6 |
life technology | 6 |
forming sequences | 6 |
short interfering | 6 |
peptide conjugated | 6 |
xc cells | 6 |
bsa agents | 6 |
none group | 6 |
virus fusion | 6 |
induced apoptosis | 6 |
restricted ctl | 6 |
inhibits type | 6 |
receptor interaction | 6 |
dimethyl sulfoxide | 6 |
assay showed | 6 |
high doses | 6 |
cell proteins | 6 |
co incubator | 6 |
human igg | 6 |
hsv tk | 6 |
clinical protection | 6 |
infection rates | 6 |
fipv replication | 6 |
one study | 6 |
covalent vaccination | 6 |
block virus | 6 |
two proteins | 6 |
japanese encephalitis | 6 |
cellular protein | 6 |
coronavirus main | 6 |
study showed | 6 |
glycoprotein gp | 6 |
confluent fcwf | 6 |
ku plaque | 6 |
ifn responses | 6 |
ionic detergents | 6 |
immune serum | 6 |
rsv hospitalization | 6 |
intraperitoneal therapy | 6 |
untreated cells | 6 |
previous reports | 6 |
ml pr | 6 |
homologous recombination | 6 |
texas medical | 6 |
least one | 6 |
tmprss cells | 6 |
target region | 6 |
map kinase | 6 |
extracellular hbv | 6 |
also provide | 6 |
expressing luciferase | 6 |
surface receptors | 6 |
molecular design | 6 |
passive immunotherapy | 6 |
dna rna | 6 |
see section | 6 |
vitro studies | 6 |
aa residues | 6 |
repeated twice | 6 |
expressing sifitm | 6 |
family filoviridae | 6 |
sequence identity | 6 |
cap structure | 6 |
fmdv infection | 6 |
attenuated rsv | 6 |
hcv polymerase | 6 |
plasma concentration | 6 |
antiviral therapeutics | 6 |
membrane protein | 6 |
molecular characterization | 6 |
flavivirus infections | 6 |
bronchial epithelial | 6 |
ring finger | 6 |
old infants | 6 |
virus polymerase | 6 |
center director | 6 |
results obtained | 6 |
airway epithelial | 6 |
functional characterization | 6 |
nucleoside triphosphate | 6 |
animal health | 6 |
transport inhibitor | 6 |
preterm infants | 6 |
neutralizing epitopes | 6 |
inhibited hsv | 6 |
prv gd | 6 |
sendai virus | 6 |
cell subsets | 6 |
web version | 6 |
cidofovir diphosphate | 6 |
either lip | 6 |
killing activities | 6 |
recombinant vacvs | 6 |
organic chemistry | 6 |
interferon antiviral | 6 |
lymph nodes | 6 |
present work | 6 |
transcriptional editing | 6 |
circular dichroism | 6 |
cytoplasmic domain | 6 |
four different | 6 |
studies suggested | 6 |
severe diseases | 6 |
without causing | 6 |
alpha beta | 6 |
viral inhibition | 6 |
viral structural | 6 |
replicon cells | 6 |
virus activities | 6 |
polymerase extension | 6 |
modified sirnas | 6 |
dna degradation | 6 |
akt proteins | 6 |
hsv infections | 6 |
clinical features | 6 |
ribosomal rna | 6 |
recombinant virus | 6 |
inhibition constant | 6 |
lung injury | 6 |
reservoir solution | 6 |
elisa system | 6 |
binding proteins | 6 |
ctd dimer | 6 |
nk cells | 6 |
virus serotype | 6 |
medium without | 6 |
utp mm | 6 |
regression analysis | 6 |
national natural | 6 |
hep cells | 6 |
resistant variants | 6 |
infected macrophages | 6 |
enhanced green | 6 |
current status | 6 |
specific inhibition | 6 |
ii trial | 6 |
novel human | 6 |
relatively high | 6 |
novel sars | 6 |
recombinant duck | 6 |
pneumococcal infection | 6 |
low dose | 6 |
using specific | 6 |
assigned values | 6 |
vectored vaccines | 6 |
standard curve | 6 |
natural science | 6 |
cmv infections | 6 |
mediated inhibition | 6 |
values obtained | 6 |
inactivated influenza | 6 |
hcv protein | 6 |
resistant viruses | 6 |
cellular localization | 6 |
better understand | 6 |
may block | 6 |
related viruses | 6 |
experiments using | 6 |
universiteit leuven | 6 |
mediated signaling | 6 |
low micromolar | 6 |
viral peptides | 6 |
human pathogenic | 6 |
infection using | 6 |
membrane microdomains | 6 |
infection cycle | 6 |
coronavirus oc | 6 |
viral pathogenesis | 6 |
thick lung | 6 |
chronic hcv | 6 |
vaccinia ankara | 6 |
rna editing | 6 |
cysteine residues | 6 |
coronaviridae family | 6 |
polyclonal serum | 6 |
type infection | 6 |
zikv mr | 6 |
cell monolayer | 6 |
viral mrnas | 6 |
effector memory | 6 |
probably due | 6 |
target tissues | 6 |
calculated based | 6 |
ion channel | 6 |
containing chloroquine | 6 |
key role | 6 |
parent compound | 6 |
expressing ahsv | 6 |
similar result | 6 |
us gene | 6 |
vaccinated group | 6 |
quantitative real | 6 |
effective inhibitory | 6 |
nonhuman primate | 6 |
glycyrrhetinic acid | 6 |
two inhibitors | 6 |
host antiviral | 6 |
antibacterial activity | 6 |
clinical efficacy | 6 |
pcr system | 6 |
transplant recipients | 6 |
highly active | 6 |
structural domains | 6 |
mtase complex | 6 |
reading frames | 6 |
various time | 6 |
hcv drugs | 6 |
ibv challenge | 6 |
doublestranded rna | 6 |
ebv dna | 6 |
mev replication | 6 |
labeled drug | 6 |
viral membranes | 6 |
dissociation constant | 6 |
apoptotic dna | 6 |
recent developments | 5 |
primers used | 5 |
heart disease | 5 |
active substance | 5 |
antiviral strategy | 5 |
sars patients | 5 |
transient transfection | 5 |
mtt solution | 5 |
interferon gamma | 5 |
fiber protein | 5 |
sirna targeting | 5 |
binding epitope | 5 |
hiv status | 5 |
resistance selection | 5 |
flaviviridae family | 5 |
dna levels | 5 |
pregnant women | 5 |
inhibits hcv | 5 |
human rsv | 5 |
inhibits mers | 5 |
mm mgcl | 5 |
block replication | 5 |
bars represent | 5 |
mediated ho | 5 |
convalescent plasma | 5 |
spectrum activity | 5 |
initiation regions | 5 |
pro catalytic | 5 |
akt signaling | 5 |
knockout mice | 5 |
higher levels | 5 |
second dose | 5 |
virus mixture | 5 |
squaric diamides | 5 |
low levels | 5 |
avian viruses | 5 |
following formula | 5 |
small number | 5 |
interferon production | 5 |
mm ctp | 5 |
may occur | 5 |
based model | 5 |
human virology | 5 |
fusion inhibition | 5 |
viral translation | 5 |
following treatment | 5 |
inhibited viral | 5 |
conditioned media | 5 |
lelystad virus | 5 |
infection induces | 5 |
liposomes alone | 5 |
single amino | 5 |
protein interactions | 5 |
surface proteins | 5 |
effective anti | 5 |
phosphorothioate oligonucleotide | 5 |
mean age | 5 |
inhibited type | 5 |
combination treatments | 5 |
nasal wash | 5 |
iga antibody | 5 |
constitutively expressed | 5 |
hydroxyl groups | 5 |
laiv vector | 5 |
develop new | 5 |
cellular rna | 5 |
experimental infection | 5 |
glycolylneuraminic acid | 5 |
infection assay | 5 |
may represent | 5 |
induced protein | 5 |
repeat regions | 5 |
may differ | 5 |
microbial infections | 5 |
biological properties | 5 |
chip surface | 5 |
graph represents | 5 |
many years | 5 |
pair df | 5 |
determined via | 5 |
hsv replication | 5 |
major peak | 5 |
conferred protection | 5 |
resistance mutations | 5 |
time course | 5 |
different groups | 5 |
virucidal effects | 5 |
iii trials | 5 |
inhibit growth | 5 |
breast cancer | 5 |
mixed inhibition | 5 |
full length | 5 |
intranasal immunization | 5 |
cytometric analysis | 5 |
minor modifications | 5 |
specific receptor | 5 |
antiretroviral activity | 5 |
common cause | 5 |
strain fipv | 5 |
ibv vaccines | 5 |
lesser extent | 5 |
cellular egfr | 5 |
electron microscopy | 5 |
bp fragment | 5 |
results also | 5 |
viruses including | 5 |
receptor type | 5 |
fusion process | 5 |
replication complexes | 5 |
hsv activity | 5 |
rna sequences | 5 |
drug arbidol | 5 |
epigallocatechin gallate | 5 |
remove unbound | 5 |
cpe inhibition | 5 |
antiviral nucleos | 5 |
culture collection | 5 |
term dosing | 5 |
airway epithelium | 5 |
novel approach | 5 |
ectopic expression | 5 |
antiviral protein | 5 |
acute phase | 5 |
ge healthcare | 5 |
newborn mice | 5 |
specific igg | 5 |
inhibitory action | 5 |
pharmacokinetic studies | 5 |
also cause | 5 |
radiolabeled probe | 5 |
coding sequences | 5 |
viral pgrna | 5 |
commercially available | 5 |
dna virus | 5 |
cytokine release | 5 |
density gradient | 5 |
recently approved | 5 |
genetics system | 5 |
host responses | 5 |
described earlier | 5 |
gradient centrifugation | 5 |
significant decrease | 5 |
antigenically related | 5 |
biosynthesis pathway | 5 |
siga technologies | 5 |
markedly inhibited | 5 |
inhibition pattern | 5 |
force field | 5 |
randomly assigned | 5 |
complete genome | 5 |
host protein | 5 |
virus ankara | 5 |
cell destruction | 5 |
postexposure protection | 5 |
active component | 5 |
tyrosine kinases | 5 |
orthopoxvirus infections | 5 |
antigen processing | 5 |
ns methyltransferase | 5 |
vaccine production | 5 |
cerebrospinal fluid | 5 |
therapeutic treatment | 5 |
five mice | 5 |
west africa | 5 |
signal transduction | 5 |
specific mabs | 5 |
peptidyl substrates | 5 |
oligomers targeting | 5 |
hydrogen bonds | 5 |
major structural | 5 |
molecular structure | 5 |
induce ifn | 5 |
vaccines based | 5 |
active nucleotide | 5 |
subgenomic replicon | 5 |
infectious viral | 5 |
thaw cycles | 5 |
prostate cancer | 5 |
intranasal route | 5 |
via different | 5 |
unless otherwise | 5 |
found online | 5 |
surface expression | 5 |
will also | 5 |
exhibited significant | 5 |
severe pneumonia | 5 |
six peptides | 5 |
monitored daily | 5 |
hokkaido university | 5 |
parainfluenza type | 5 |
potently inhibited | 5 |
hcv therapy | 5 |
studies conducted | 5 |
experimental influenza | 5 |
virus plaques | 5 |
specific pathogen | 5 |
specific lysis | 5 |
rsv antibodies | 5 |
following infection | 5 |
beneficial effects | 5 |
less frequently | 5 |
site sequence | 5 |
data collection | 5 |
cells inhibition | 5 |
capsid proteins | 5 |
group group | 5 |
serial dilution | 5 |
viral rnas | 5 |
bird nests | 5 |
od value | 5 |
adsorption process | 5 |
negative effect | 5 |
second immunization | 5 |
virus envelope | 5 |
i ifns | 5 |
virus neutralising | 5 |
one cat | 5 |
pcr product | 5 |
plates containing | 5 |
inhibits hiv | 5 |
cancer drug | 5 |
obtained using | 5 |
major public | 5 |
propidium iodide | 5 |
rich regions | 5 |
drug therapy | 5 |
vif shrna | 5 |
sensor chip | 5 |
viral enzyme | 5 |
sulfated polysaccharides | 5 |
arb antiviral | 5 |
also able | 5 |
gene encoding | 5 |
diabzi treatment | 5 |
serum antibodies | 5 |
dennis hruby | 5 |
cov polymerase | 5 |
affected countries | 5 |
decoy tar | 5 |
targeting vivo | 5 |
incubated overnight | 5 |
colleagues reported | 5 |
nsp nsp | 5 |
ace binding | 5 |
lm range | 5 |
old female | 5 |
drug may | 5 |
chris meier | 5 |
address whether | 5 |
fatal disease | 5 |
hcv subgenomic | 5 |
cold pbs | 5 |
phylogenetic analysis | 5 |
respectively whereas | 5 |
novel viral | 5 |
spiked plasma | 5 |
leading cause | 5 |
developing countries | 5 |
alpha interferon | 5 |
arb may | 5 |
human populations | 5 |
hiv reverse | 5 |
adapted influenza | 5 |
also found | 5 |
ifnr antibody | 5 |
will likely | 5 |
mouse interferon | 5 |
inhibitory properties | 5 |
high prevalence | 5 |
concentrations ranging | 5 |
controlled trial | 5 |
years later | 5 |
ml concentration | 5 |
viral binding | 5 |
causes severe | 5 |
free medium | 5 |
young investigators | 5 |
south america | 5 |
based rsv | 5 |
represents means | 5 |
treat fcv | 5 |
core facility | 5 |
molecule antiviral | 5 |
several different | 5 |
reverse transcribed | 5 |
capping enzymes | 5 |
complete termination | 5 |
selected cytokines | 5 |
inflammatory disease | 5 |
also inhibit | 5 |
late promoter | 5 |
late apoptosis | 5 |
chronic active | 5 |
highly protective | 5 |
coronavirus nonstructural | 5 |
bacterial pneumonia | 5 |
arbitrarily drawn | 5 |
igg antibody | 5 |
times higher | 5 |
viral tk | 5 |
hp inhibited | 5 |
medical virology | 5 |
people worldwide | 5 |
results clearly | 5 |
cells containing | 5 |
saturable target | 5 |
synergistic antiviral | 5 |
ubiquitinated cellular | 5 |
northern blot | 5 |
peptides including | 5 |
mortality rate | 5 |
protein sequence | 5 |
congenital heart | 5 |
pharmacologically active | 5 |
direct antiviral | 5 |
signaling technology | 5 |
high genetic | 5 |
sam molecule | 5 |
significant morbidity | 5 |
cellular immunity | 5 |
atpase activity | 5 |
ebolavirus gp | 5 |
membranous web | 5 |
membrane proteins | 5 |